<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03194269</url>
  </required_header>
  <id_info>
    <org_study_id>CMO-EAME-FAS-0469</org_study_id>
    <nct_id>NCT03194269</nct_id>
  </id_info>
  <brief_title>Long Term Prospective Uncontrolled Study Of Earfold™ For The Treatment Of Prominent Ears</brief_title>
  <acronym>FOLD</acronym>
  <official_title>FOLD: Long Term Prospective Uncontrolled Study Of Earfold™ For The Treatment Of Prominent Ears</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, prospective, uncontrolled, single arm, post-marketing study of the
      long-term safety and performance of EARFOLD® Implantable Clip System.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 17, 2017</start_date>
  <completion_date type="Anticipated">October 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 28, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline pre-insertion in EAR-Q Ears Appearance Questionnaire score</measure>
    <time_frame>Baseline to month 3</time_frame>
    <description>EAR-Q Ears Appearance Questionnaire is on a 4 point scale (1=Not at all, 2=A little bit, 3=Quite a bit, 4=Very much)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline pre-insertion in EAR-Q Ears Appearance overall score at 12 months post-implantation</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>EAR-Q Ears Appearance Questionnaire is on a 4 point scale (1=Not at all, 2=A little bit, 3=Quite a bit, 4=Very much)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline pre-insertion in EAR-Q Ears Appearance overall score at 24 months post-implantation</measure>
    <time_frame>Baseline to Month 24</time_frame>
    <description>EAR-Q Ears Appearance Questionnaire is on a 4 point scale (1=Not at all, 2=A little bit, 3=Quite a bit, 4=Very much)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients that require re-operation at any moment</measure>
    <time_frame>24 months</time_frame>
    <description>Percentage of patients that require re-operation at any moment during the investigational period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with recurrence of ear prominence</measure>
    <time_frame>24 months</time_frame>
    <description>Percentage of patients with recurrence of ear prominence at any moment during the investigational period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of Short Form-12 score at Month 3 for subjects over 18 years</measure>
    <time_frame>Baseline to Month 3</time_frame>
    <description>The Short Form-12 Health Survey will be administered to subjects over 18 years old to measure health and well-being</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of Short Form-12 score at Month 12 for subjects over 18 years</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>The Short Form-12 Health Survey will be administered to subjects over 18 years old to measure health and well-being</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of Short Form-12 score at Month 24 for subjects over 18 years</measure>
    <time_frame>Baseline to Month 24</time_frame>
    <description>The Short Form-12 Health Survey will be administered to subjects over 18 years old to measure health and well-being</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of Short Form-10 score at Month 3 for subjects under 18 years old</measure>
    <time_frame>Baseline to Month 3</time_frame>
    <description>The Short Form-10 Health Survey will be administered to subjects under 18 years old to measure health and well-being</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of Short Form-10 score at Month 12 for subjects under 18 years old</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>The Short Form-10 Health Survey will be administered to subjects under 18 years old to measure health and well-being</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of Short Form-10 score at Month 24 for subjects under 18 years old</measure>
    <time_frame>Baseline to Month 24</time_frame>
    <description>The Short Form-10 Health Survey will be administered to subjects under 18 years old to measure health and well-being</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in maximum helix to scalp distance from before PREFOLD® insertion at Month 3</measure>
    <time_frame>Baseline to Month 3</time_frame>
    <description>Helix to scalp distance with untreated ears compared to EARFOLD in</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in maximum helix to scalp distance from before PREFOLD® insertion at Month 12</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>Helix to scalp distance with untreated ears compared to EARFOLD in</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in maximum helix to scalp distance from before PREFOLD® insertion at Month 24</measure>
    <time_frame>Baseline to Month 24</time_frame>
    <description>Helix to scalp distance with untreated ears compared to EARFOLD in</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance of maximum helix to scalp distance at 12 months compared to 3 months visit post insertion of EARFOLD</measure>
    <time_frame>Month 3 to Month 12</time_frame>
    <description>Helix to scalp distance with EARFOLD inserted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance of maximum helix to scalp distance at 24 months compared to 3 months visit post insertion of EARFOLD</measure>
    <time_frame>Month 3 to Month 24</time_frame>
    <description>Helix to scalp distance with EARFOLD inserted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in maximum helix to scalp distance from PREFOLD® insertion to post insertion distances at Month 3</measure>
    <time_frame>Baseline to Month 3</time_frame>
    <description>Helix to scalp distance with PREFOLD® in compared with EARFOLD in</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in maximum helix to scalp distance from PREFOLD® insertion to post insertion distances at Month 12</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>Helix to scalp distance with PREFOLD® in compared with EARFOLD in</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in maximum helix to scalp distance from PREFOLD® insertion to post insertion distances at Month 24</measure>
    <time_frame>Baseline to Month 24</time_frame>
    <description>Helix to scalp distance with PREFOLD® in compared with EARFOLD in</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of EARFOLD® insertion procedure</measure>
    <time_frame>Duration of surgery</time_frame>
    <description>From the first incision of the scalpel to the last application of the sterristrip over the wound, duration of surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline pre-insertion in EAR-Q Social Function Questionnaire at Month 3</measure>
    <time_frame>Baseline to Month 3</time_frame>
    <description>EAR-Q Social Function Questionnaire is on a 4 point scale (1=Never, 2=Sometimes, 3=Often, 4=Always)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline pre-insertion in EAR-Q Social Function Questionnaire at Month 12</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>EAR-Q Social Function Questionnaire is on a 4 point scale (1=Never, 2=Sometimes, 3=Often, 4=Always)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline pre-insertion in EAR-Q Social Function Questionnaire at Month 24</measure>
    <time_frame>Baseline to Month 24</time_frame>
    <description>EAR-Q Social Function Questionnaire is on a 4 point scale (1=Never, 2=Sometimes, 3=Often, 4=Always)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline pre-insertion in EAR-Q School Function Questionnaire at Month 3</measure>
    <time_frame>Baseline to Month 3</time_frame>
    <description>EAR-Q School Function Questionnaire is on a 4 point scale (1=Never, 2=Sometimes, 3=Often, 4=Always)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline pre-insertion in EAR-Q School Function Questionnaire at Month 12</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>EAR-Q School Function Questionnaire is on a 4 point scale (1=Never, 2=Sometimes, 3=Often, 4=Always)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline pre-insertion in EAR-Q School Function Questionnaire at Month 24</measure>
    <time_frame>Baseline to Month 24</time_frame>
    <description>EAR-Q School Function Questionnaire is on a 4 point scale (1=Never, 2=Sometimes, 3=Often, 4=Always)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline pre-insertion in EAR-Q Psychological Function Questionnaire at Month 3</measure>
    <time_frame>Baseline to Month 3</time_frame>
    <description>EAR-Q Psychological Function Questionnaire is on a 4 point scale (1=Never, 2=Sometimes, 3=Often, 4=Always)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline pre-insertion in EAR-Q Psychological Function Questionnaire at Month 12</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>EAR-Q Psychological Function Questionnaire is on a 4 point scale (1=Never, 2=Sometimes, 3=Often, 4=Always)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline pre-insertion in EAR-Q Psychological Function Questionnaire at Month 24</measure>
    <time_frame>Baseline to Month 24</time_frame>
    <description>EAR-Q Psychological Function Questionnaire is on a 4 point scale (1=Never, 2=Sometimes, 3=Often, 4=Always)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Return to normal activities questionnaire after EARFOLD® surgery at Month 3</measure>
    <time_frame>Month 3</time_frame>
    <description>Return to normal activities questionnaire is on a 11-point scale ranging from 10=strongly agree to 0=strongly disagree</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Prominent Ears</condition>
  <arm_group>
    <arm_group_label>EARFOLD®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EARFOLD® implant is inserted subcutaneously using the sterile disposable EARFOLD® introducer under local anaesthetic</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EARFOLD®</intervention_name>
    <description>EARFOLD® implant is inserted subcutaneously using the sterile disposable EARFOLD® introducer under local anaesthetic</description>
    <arm_group_label>EARFOLD®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who have ear prominence and/or have significant asymmetry

        Exclusion Criteria:

          -  Subjects planning to use EARFOLD® in conjunction with other procedures (e.g. cartilage
             scoring, conchal reduction or concho-mastoid sutures) for correction of prominent ears
             are excluded

          -  Patients with impaired healing (e.g., current smokers, diabetic patients, patients
             with autoimmune disorders such as Ehlers-Danlos Syndrome or Scleroderma)

          -  Patients with an active infection, local or systemic

          -  Patients with known nickel or gold allergies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Silberberg</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Registry Team</last_name>
    <phone>877-277-8566</phone>
    <email>IR-CTRegistration@allergan.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://AllerganClinicalTrials.com</url>
    <description>Additional information on study locations near you may be found at AllerganClinicalTrials.com. For any study not on AllerganClinicalTrials.com, please contact IR-CTRegistration@Allergan.com for assistance.</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2017</study_first_submitted>
  <study_first_submitted_qc>June 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2017</study_first_posted>
  <last_update_submitted>August 21, 2017</last_update_submitted>
  <last_update_submitted_qc>August 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

